Talk:Α-Methyl-p-tyrosine

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Neuroscience Low‑importance

	This article is within the scope of WikiProject Neuroscience, a collaborative effort to improve the coverage of Neuroscience on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.NeuroscienceWikipedia:WikiProject NeuroscienceTemplate:WikiProject Neuroscienceneuroscience articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Α-Methyl-p-tyrosine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

From Pubchem: "An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)" Fuzzform (talk) 08:01, 18 December 2007 (UTC)[reply]

uses

Has AMPT been used to force an increase in dopamine receptors to shorten cocaine withdrawals or to increase the effectiveness of drugs like wellbutrin after wellbutrin has become less effective? Has it been used for it's rebound effect to fight atypical depression? Alatari (talk) 05:40, 18 June 2009 (UTC)[reply]

AMPT is the opposite of an anti-depression drug. It reduces the amount of dopamine in the body. Dopamine becomes serotonin. And Serotonin cures depression. Alpha-methyl-p-tyrosine inhibits the synthesis of Tyrosine -> L-Dopa -> Dopamine -> Serotonin. People who take a lot of Alpha-methyl-p-tyrosine or take it long term are likely to see drastically reduced dopamine levels, hence more depression.

For the cocaine addiction, it would work some for a little bit. The point of this therapy would be to take away the ability for serotonin, dopamine and epinephrine from playing their normal roles. Since Alpha-methyl-p-tyrosine inhibits the synthesis of Tyrosine -> which eventually becomes serotonin, dopamine and epinephrine. If they are not getting the good feelings anymore, after they take AMPT for a while & then blow some more lines -> then their addiction would be somewhat broken.

For non-cocaine users you would want to find out how to DECREASE your levels of AMPT & thereby increase your absortion rate of Tyrosine into the various Catecholamines (serotonin, dopamine and epinephrine). I have not found anything on how to do this yet. You would have to identify the pre-cursors to AMPT, then determine how you can reduce those levels. Good Luck —Preceding unsigned comment added by 66.66.132.42 (talk) 14:32, 16 April 2011 (UTC)[reply]

Merge discussion

The following discussion is closed. Please do not modify it. Subsequent comments should be made in a new section. A summary of the conclusions reached follows.

The result of this discussion was merge. Michael D. Turnbull, when you get a chance, can you merge the drugboxes? I can help with other post-merge cleanup. Mdewman6 (talk) 18:09, 20 October 2023 (UTC)[reply]

It looks like Metirosine should probably be merged here. The latter is about the L enantiomer (the bioactive form?) and this article is about the racemate, but except for drugbox differences, they are written like duplicate articles, with no mention of the distinction between the two, and just a casual link in the lede of Metirosine to here via the old title AMPT. Racemetirosine, which as the name implies, refers to the racemic mixture, incorrectly redirected to Metirosine until I just retargeted it. So, if these are to be separate articles, they need to be clearly differentiated from each other, otherwise they should probably be merged given the overlap, and the distinction described there. However, if merged, merging the drugbox content will take a lot of time and care, and there is probably someone better suited than me for that. There was previously thoughts about merging at Talk:Metirosine. Thoughts? Mdewman6 (talk) 21:58, 20 September 2023 (UTC)[reply]

Merge: the notable material is the drug, which I think is the (2S) isomer. The pubchem entries are a bit of a mess but the correct InChI key seems to be NHTGHBARYWONDQ-JTQLQIEISA-N, which is what Wikidata says. The Chemspider entry lists both the (2R) and the (2S) isomer as "Metirosine", so this all needs to be checked carefully against the original sources. I'm familiar with using the drugbox/chembox to list several isomeric materials, so I'll volunteer to do that part, once we have a consensus for the merge. Mike Turnbull (talk) 14:38, 21 September 2023 (UTC)[reply]

Pinging TheBartgry who commented on the other talk page about a merge previously.

Merge. Seems noncontroversial. --Smokefoot (talk) 17:43, 15 October 2023 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.